Genomenon
Genomenon: Comprehensive genomic evidence provider, aiding in critical biomarker identification.
Founded
2014Genomenon: Comprehensive genomic evidence provider, aiding in critical biomarker identification.
Genomenon, founded with the mission to provide comprehensive genomic evidence, focuses on transforming complex genetic data into actionable insights. The company offers advanced software solutions for identifying critical biomarkers, particularly in next-generation sequencing (NGS). Their core products and services cater to precision medicine and clinical diagnostics, supporting the development of therapeutics for genetic diseases and cancer. Genomenon aims to be the leading source of genomic intelligence, aiding healthcare professionals in making informed decisions.
Notable affiliations include partnerships with key players in precision medicine and clinical diagnostics. Genomenon's acquisition of the JAX Clinical Knowledgebase marks a significant achievement, enhancing their genomic curation capabilities. The company's impact is evident in its ability to accelerate NGS variant interpretation, thereby advancing the field of genetic research and improving patient outcomes. Through its innovative solutions, Genomenon continues to play a pivotal role in the integration of genomic data into clinical practice.
Companies similar to Genomenon include GenomeNext, Station X, Gencove and GenomOncology.
Genomenon was founded in 2014.
Genomenon's headquarters is located in Ann Arbor, MI, US.
Genomenon's most recent funding round was for $20M (USD) in March 2022.
As of Mar 8, 2022, Genomenon has disclosed funding of $32.8M (USD). Undisclosed round amounts are excluded.
Genomenon has 80 employees as of Feb 5, 2024.
genomoncology.com
